Ticker

WESTFIELD, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- JATT II Acquisition Corp (the “Company”), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the pricing of its initial public offering of 6,000,000 ordinary shares at an offering price of $10.00 per ordinary share. The ordinary shares are expected to trade on the Nasdaq Global Market (“NASDAQ”) under…

Protalix BioTherapeutics (NYSE: PLX - Get Free Report) and JATT Acquisition (NYSE: JATT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations. Insider and Institutional Ownership 16.5% of Protalix